A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia
Victoria C. Wing,
Caroline E. Wass,
Debra W. Soh,
Tony P. George,
Victoria C. Wing
Addiction Psychiatry Program, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Schizophrenia Program, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada
Search for more papers by this authorCaroline E. Wass
Addiction Psychiatry Program, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Schizophrenia Program, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada
Search for more papers by this authorDebra W. Soh
Schizophrenia Program, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada
Search for more papers by this authorTony P. George
Addiction Psychiatry Program, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Schizophrenia Program, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada
Search for more papers by this authorVictoria C. Wing,
Caroline E. Wass,
Debra W. Soh,
Tony P. George,
Victoria C. Wing
Addiction Psychiatry Program, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Schizophrenia Program, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada
Search for more papers by this authorCaroline E. Wass
Addiction Psychiatry Program, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Schizophrenia Program, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada
Search for more papers by this authorDebra W. Soh
Schizophrenia Program, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada
Search for more papers by this authorTony P. George
Addiction Psychiatry Program, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Schizophrenia Program, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada
Search for more papers by this authorDr. Tony George, Centre for Addiction and Mental Health, 250 College Street, Room CS 734, Toronto, Ontario, Canada M5T 1R8. [email protected]
Abstract
There is converging evidence that certain subpopulations of smokers, such as smokers with a serious mental illness like schizophrenia (SCZ), are more likely to become addicted to tobacco and are less likely to quit smoking. This review focuses on the unique risk factors that may increase vulnerability to the initiation and maintenance of nicotine addiction in persons with schizophrenia and other psychotic disorders and also reviews the latest approaches to treating nicotine addiction and schizophrenia based on our neurobiological understanding of central nicotinic receptor systems and related neurotransmitters. In addition, suggestions for future lines of research to better understand reasons for the comorbidity of nicotine addiction in schizophrenia are discussed.
References
- 1 Morisano, D., I. Bacher, J. Audrain-McGovern & T.P. George. 2009. Mechanisms underlying the comorbidity of tobacco use in mental health and addictive disorders. Can. J. Psychiatr. 54: 356–367.
- 2 Lasser, K., J.W. Boyd, S. Woolhandler, et al . 2000. Smoking and mental illness: a population-based prevalence study. JAMA 284: 2606–2610.
- 3 Ziedonis, D., B. Hitsman, J.C. Beckham, et al . 2008. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob. Res. 10: 1691–1715.
- 4 George, T.P. & D.M. Ziedonis. 2009. Addressing tobacco dependence in psychiatric practice: promises and pitfalls. Can. J. Psychiatr. 54: 353–355.
- 5 Moss, T.G., A.H. Weinberger, J.C. Vessicchio, et al . 2010. A tobacco reconceptualization in psychiatry: toward the development of tobacco-free psychiatric facilities. Am. J. Addict. 19: 293–311.
- 6
George, T.P.
2007. Neurobiological links between nicotine addiction and schizophrenia.
J. Dual Diagn.
3: 27–42.
10.1300/J374v03n03_04 Google Scholar
- 7 Winterer, G. 2010. Why do patients with schizophrenia smoke? Curr. Opin. Psychiatr. 23: 112–119.
- 8 Chambers, R.A. 2009. A nicotine challenge to the self-medication hypothesis in a neurodevelopmental animal model of schizophrenia. J. Dual Diagn. 5: 139–148.
- 9 Picciotto, M.R., B.J. Caldarone, S.L. King & V. Zachariou. 2000. Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology 22: 451–465.
- 10 Pidoplichko, V.I., M. DeBiasi, J.T. Williams & J.A. Dani. 1997. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390: 401–404.
- 11 Gentry, C.L. & R.J. Lukas. 2002. Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. Curr. Drug Targets—CNS Neurol. Disord. 1: 359–385.
- 12 Albuquerque, E.X., E.F. Pereira, M. Alkondon & S.W. Rogers. 2009. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev. 89: 73–120.
- 13 Di Chiara, G. & A. Imperato. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA 85: 5274–5278.
- 14 Schilstrom, B., H.M. Svensson, T.H. Svensson & G.G. Nomikos. 1998. Nicotine and food induced dopamine release in the nucleus accumbens of the rat: putative role of alpha7 nicotinic receptors in the ventral tegmental area. Neuroscience 85: 1005–1009.
- 15 Zoli, M., M. Moretti, A. Zanardi, et al . 2002. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J. Neurosci. 22: 8785–8789.
- 16 Mansvelder, H.D., J.R. Keath & D.S. McGehee. 2002. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33: 905–919.
- 17 Keath, J.R., M.P. Iacoviello, L.E. Barrett, et al . 2007. Differential modulation by nicotine of substantia nigra versus ventral tegmental area dopamine neurons. J. Neurophysiol. 98: 3388–3396.
- 18 Laviolette, S.R. & D. van derKooy. 2004. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat. Rev. Neurosci. 5: 55–65.
- 19 Marshall, D.L., P.H. Redfern & S. Wonnacott. 1997. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J. Neurochem. 68: 1511–1519.
- 20 Erhardt, S., L. Schwieler & G. Engberg. 2002. Excitatory and inhibitory responses of dopamine neurons in the ventral tegmental area to nicotine. Synapse 43: 227–237.
- 21 Sesack, S.R. & A.A. Grace. 2010. Cortico-Basal Ganglia reward network: microcircuitry. Neuropsychopharmacol. 35: 27–47.
- 22 Schilstrom, B., G.G. Nomikos, M. Nisell, et al . 1998. N-methyl-D-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience 82: 781–789.
- 23 McGehee, D.S., M.J. Heath, S. Gelber, et al . 1995. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 269: 1692–1696.
- 24 George, T.P., C.D. Verrico, M.R. Picciotto & R.H. Roth. 2000. Nicotinic modulation of mesoprefrontal dopamine neurons: pharmacologic and neuroanatomic characterization. J. Pharmacol. Exp. Ther. 295: 58–66.
- 25 Livingstone, P.D., J. Srinivasan, J.N.C. Kew, et al . 2009. Alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur. J. Neurosci. 29: 539–550.
- 26 Sacco, K.A., A. Termine, A. Seyal, et al . 2005. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch. Gen. Psychiatr. 62: 649–659.
- 27 George, T.P., J.C. Vessicchio, A. Termine, et al . 2002. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacol. 26: 75–85.
- 28 Couey, J.J., R.M. Meredith, S. Spijker, et al . 2007. Distributed network actions by nicotine increase the threshold for spike-timing-dependent plasticity in prefrontal cortex. Neuron 54: 73–87.
- 29 Livingstone, P.D., J.A. Dickinson, J. Srinivasan, et al . 2010. Glutamate-dopamine crosstalk in the rat prefrontal cortex is modulated by alpha7 nicotinic receptors and potentiated by PNU-120596. J. Mol. Neurosci. 40: 172–176.
- 30 McGehee, D.S. 2007. Nicotine and synaptic plasticity in prefrontal cortex. Sci. STKE 2007: pe44.
- 31 Abi-Dargham, A. & H. Moore. 2003. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 9: 404–416.
- 32 Gray, R., A.S. Rajan, K.A. Radcliffe, et al . 1996. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 383: 713–716.
- 33 Freedman, R., C.E. Adams & S. Leonard. 2000. The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J. Chem. Neuroanat. 20: 299–306.
- 34 Abi-Dargham, A., R. Gil, J. Krystal, et al . 1998. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatr. 155: 761–767.
- 35 Farde, L., F.A. Wiesel, C. Halldin & G. Sedvall. 1988. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatr. 45: 71–76.
- 36 Goldman-Rakic, P.S., S.A. Castner, T.H. Svensson, et al . 2004. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 174: 3–16.
- 37 Brody, A.L., R.E. Olmstead, E.D. London, et al . 2004. Smoking-induced ventral striatum dopamine release. Am. J. Psychiatr. 161: 1211–1218.
- 38 Javitt, D.C. 2007. Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int. Rev. Neurobiol. 78: 69–108.
- 39 Gao, X.M., K. Sakai, R.C. Roberts, et al . 2000. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am. J. Psychiatr. 157: 1141–1149.
- 40 Ghose, S., K.A. Gleason, B.W. Potts, et al . 2009. Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? Am. J. Psychiatr. 166: 812–820.
- 41 Sesack, S.R. & D.B. Carr. 2002. Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia. Physiol. Behav. 77: 513–517.
- 42 Lewis, D.A. & G. Gonzalez-Burgos. 2008. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacol. 33: 141–165.
- 43 Carlsson, A. & M.L. Carlsson. 2006. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin. Neurosci. 8: 137–142.
- 44 Tost, H. & A. Meyer-Lindenberg. 2011. Dopamine-glutamate interactions: a neural convergence mechanism of common schizophrenia risk variants. Biol. Psychiatr. 69: 912–913.
- 45 Weinberger, D.R., K.F. Berman & R.F. Zec. 1986. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia: I. Regional cerebral blood flow evidence. Arch. Gen. Psychiatr. 43: 114–124.
- 46 Gonzalez-Burgos, G., T. Hashimoto & D.A. Lewis. 2010. Alterations of cortical GABA neurons and network oscillations in schizophrenia. Curr. Psychiatr. Rep. 12: 335–344.
- 47 Lewis, D.A. & B. Moghaddam. 2006. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch. Neurol. 63: 1372–1376.
- 48 Akbarian, S., J.J. Kim, S.G. Potkin, et al . 1995. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatr. 52: 258–266.
- 49 Heckers, S. & C. Konradi. 2002. 36 Hippocampal neurons in schizophrenia. J. Neural Transm. 109: 891–905.
- 50 Maloku, E., B. Kadriu, A. Zhubi, et al . 2011. Selective alpha(4)beta(2) nicotinic acetylcholine receptor agonists target epigenetic mechanisms in cortical GABAergic neurons. Neuropsychopharmacol. 36: 1366–1374.
- 51 Court, J., D. Spurden, S. Lloyd, et al . 1999. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J. Neurochem. 73: 1590–1597.
- 52 Guan, Z.Z., X. Zhang, K. Blennow & A. Nordberg. 1999. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 10: 1779–1782.
- 53 Breese, C.R., M.J. Lee, C.E. Adams, et al . 2000. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacol. 23: 351–364.
- 54 D'Souza, D.C., I. Esterlis, M. Krasenics, et al . 2011. Decreased beta2*-nAChR receptor availability in recently abstinent smokers with schizophrenia. Biol. Psychiatry 69: 204S.
- 55 Mexal, S., R. Berger, J. Logel, et al . 2010. Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers. J. Mol. Neurosci. 40: 185–195.
- 56 Freedman, R., H. Coon, M. Myles-Worsley, et al . 1997. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. USA 94: 587–592.
- 57 Freedman, R., S. Leonard, M. Waldo, et al . 2006. Characterization of allelic variants at chromosome 15q14 in schizophrenia. Genes Brain Behav. 5(Suppl 1): 14–22.
- 58
Leonard, S.,
J. Gault,
T. Moore,
et al
. 1998. Further investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibpairs from the NIMH Genetics Initiative.
Am. J. Med. Genet.
81: 308–312.
10.1002/(SICI)1096-8628(19980710)81:4<308::AID-AJMG6>3.0.CO;2-P CASPubMedWeb of Science®Google Scholar
- 59 De Luca, V., S. Voineskos, G. Wong, & J.L. Kennedy. 2006. Genetic interaction between alpha4 and beta2 subunits of high affinity nicotinic receptor: analysis in schizophrenia. Exp. Brain Res. 174: 292–296.
- 60 Hong, L.E., X. Yang, I. Wonodi, et al . 2011. A CHRNA5 allele related to nicotine addiction and schizophrenia. Genes Brain Behav. 10: 530–535.
- 61 Petrovsky, N., B.B. Quednow, U. Ettinger, et al . 2010. Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers. Neuropsychopharmacol. 35: 1429–1439.
- 62 Faraone, S.V., J. Su, L. Taylor, et al . 2004. A novel permutation testing method implicates sixteen nicotinic acetylcholine receptor genes as risk factors for smoking in schizophrenia families. Hum. Hered. 57: 59–68.
- 63 De Luca, V., A.H. Wong, D.J. Muller, et al . 2004. Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacol. 29: 1522–1526.
- 64 Leonard, S., S. Mexal & R. Freedman. 2007. Smoking, genetics and schizophrenia: evidence for self medication. J. Dual Diagn. 3: 43–59.
- 65 Green, M.F., R.S. Kern & R.K. Heaton. 2004. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res. 72: 41–51.
- 66 Andreasen, N.C. 2000. Schizophrenia: the fundamental questions. Brain Res. Rev. 31: 106–112.
- 67 Braff, D.L. 1993. Information processing and attention dysfunctions in schizophrenia. Schizophr. Bull. 19: 233–259.
- 68 Heinrichs, R.W. & K.K. Zakzanis. 1998. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12: 426–445.
- 69 Nagamoto, H.T., L.E. Adler, M.C. Waldo, et al . 1991. Gating of auditory response in schizophrenics and normal controls. Effects of recording site and stimulation interval on the P50 wave. Schizophr. Res. 4: 31–40.
- 70 Adler, L.E., E. Pachtman, R.D. Franks, et al . 1982. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol. Psychiatr. 17: 639–654.
- 71 Olincy, A., D.L. Braff, L.E. Adler, et al . 2010. Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: results from the gonsortium on genetics of schizophrenia. Schizophr. Res. 119: 175–182.
- 72 Adler, L.E., L.D. Hoffer, A. Wiser & R. Freedman. 1993. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am. J. Psychiatr. 150: 1856–1861.
- 73 Chen, X.S., C.B. Li, R.C. Smith, et al . 2011. Differential sensory gating functions between smokers and non-smokers among drug-naive first episode schizophrenic patients. Psychiatr. Res. 188: 327–333.
- 74 Adler, L.E., L.J. Hoffer, J. Griffith, et al . 1992. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol. Psychiatr. 32: 607–616.
- 75 Knott, V., A. Millar, D. Fisher & P. Albert. 2010. Effects of nicotine on the amplitude and gating of the auditory P50 and its influence by dopamine D2 receptor gene polymorphism. Neuroscience 166: 145–156.
- 76 Knott, V.J., D.J. Fisher & A.M. Millar. 2010. Differential effects of nicotine on P50 amplitude, its gating, and their neural sources in low and high suppressors. Neuroscience 170: 816–826.
- 77 Millar, A., D. Smith, J. Choueiry, et al . 2011. The moderating role of the dopamine transporter 1 gene on P50 sensory gating and its modulation by nicotine. Neuroscience 180: 148–156.
- 78 Leonard, S., J. Gault, J. Hopkins, et al . 2002. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch. Gen. Psychiatr. 59: 1085–1096.
- 79 Leonard, S., C. Adams, C.R. Breese, et al . 1996. Nicotinic receptor function in schizophrenia. Schizophr. Bull. 22: 431–445.
- 80 Braff, D.L., C. Grillon & M.A. Geyer. 1992. Gating and habituation of the startle reflex in schizophrenic patients. Arch. Gen. Psychiatr. 49: 206–215.
- 81 Cadenhead, K.S., N.R. Swerdlow, K.M. Shafer, et al . 2000. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits. Am. J. Psychiatr. 157: 1660–1668.
- 82 Hasenkamp, W., M.P. Epstein, A. Green, et al . 2010. Heritability of acoustic startle magnitude, prepulse inhibition, and startle latency in schizophrenia and control families. Psychiatr. Res. 178: 236–243.
- 83 Hong, L.E., I. Wonodi, J. Lewis & G.K. Thaker. 2008. Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients. Neuropsychopharmacol. 33: 2167–2174.
- 84 Postma, P., J.A. Gray, T. Sharma, et al . 2006. A behavioural and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy subjects and persons with schizophrenia. Psychopharmacology (Berl). 184: 589–599.
- 85 George, T.P., A. Termine, K.A. Sacco, et al . 2006. A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanisms. Schizophr. Res. 87: 307–315.
- 86 Woznica, A.A., K.A. Sacco & T.P. George. 2009. Prepulse inhibition deficits in schizophrenia are modified by smoking status. Schizophr. Res. 112: 86–90.
- 87 Rabin, R.A., K.A. Sacco & T.P. George. 2009. Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: effects of smoking status. Schizophr. Res. 114: 91–97.
- 88 Kumari, V., J.A. Gray, M.A. Geyer, et al . 2003. Neural correlates of tactile prepulse inhibition: a functional MRI study in normal and schizophrenic subjects. Psychiatr. Res. 122: 99–113.
- 89 Hommer, D.W., T. Clem, R. Litman & D. Pickar. 1991. Maladaptive anticipatory saccades in schizophrenia. Biol. Psychiatr. 30: 779–794.
- 90 Ross, R.G., J.G. Harris, A. Olincy, et al . 1998. Familial transmission of two independent saccadic abnormalities in schizophrenia. Schizophr. Res. 30: 59–70.
- 91 Larrison-Faucher, A.L., A.A. Matorin & A.B. Sereno. 2004. Nicotine reduces antisaccade errors in task impaired schizophrenic subjects. Prog. Neuropsychopharmacol. Biol. Psychiatr. 28: 505–516.
- 92 Olincy, A., R.G. Ross, D.A. Young, et al . 1998. Improvement in smooth pursuit eye movements after cigarette smoking in schizophrenic patients. Neuropsychopharmacol. 18: 175–185.
- 93 Olincy, A., L.L. Johnson & R.G. Ross. 2003. Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatr. Res. 117: 223–236.
- 94 Avila, M.T., J.D. Sherr, E. Hong, et al . 2003. Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacol. 28: 2184–2191.
- 95 Tanabe, J., J.R. Tregellas, L.F. Martin & R. Freedman. 2006. Effects of nicotine on hippocampal and cingulate activity during smooth pursuit eye movement in schizophrenia. Biol. Psychiatr. 59: 754–761.
- 96 Tregellas, J.R., J.L. Tanabe, L.F. Martin & R. Freedman. 2005. FMRI of response to nicotine during a smooth pursuit eye movement task in schizophrenia. Am. J. Psychiatr. 162: 391–393.
- 97 Sevik, A.E., A.E. Anil Yagcioglu, S. Yagcioglu, et al . 2011. Neuropsychological performance and auditory event related potentials in schizophrenia patients and their siblings: a family study. Schizophr. Res. 130: 195–202.
- 98 Dulude, L., A. Labelle & V.J. Knott. 2010. Acute nicotine alteration of sensory memory impairment in smokers with schizophrenia. J. Clin. Psychopharmacol. 30: 541–548.
- 99 Levin, E.D., W. Wilson, J.E. Rose & J. McEvoy. 1996. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacol. 15: 429–436.
- 100 Harris, J.G., S. Kongs, D. Allensworth, et al . 2004. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacol. 29: 1378–1385.
- 101 Jacobsen, L.K., D.C. D'Souza, W.E. Mencl, et al . 2004. Nicotine effects on brain function and functional connectivity in schizophrenia. Biol. Psychiatr. 55: 850–858.
- 102 Smith, R.C., A. Singh, M. Infante, et al . 2002. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacol. 27: 479–497.
- 103 Smith, R.C., J. Warner-Cohen, M. Matute, et al . 2006. Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacol. 31: 637–643.
- 104 Depatie, L., G.A. O’Driscoll, A.-L.V. Holahan, et al . 2002. Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study. Neuropsychopharmacol. 27: 1056–1070.
- 105 Wing, V.C., K.A. Sacco & T.P. George. 2011. Spatial working memory impairments induced by cigarette smoking abstinence are correlated with plasma nicotine levels in schizophrenia. Schizophr. Res. 128: 171–172.
- 106 Wing, V.C., I. Bacher, K.A. Sacco & T.P. George. 2011. Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status. Psychiatr. Res. 180: 320–326.
- 107 Dolan, S.L., K.A. Sacco, A. Termine, et al . 2004. Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia. Schizophr. Res. 70: 263–275.
- 108 Moss, T.G., K.A. Sacco, T.M. Allen, et al . 2009. Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia. Drug Alcohol Depend. 104: 94–99.
- 109 Hong, L.E., M. Schroeder, T.J. Ross, et al . 2011. Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. Schizophr. Bull. 37: 416–425.
- 110 Newhouse, P., A. Singh & A. Potter. 2004. Nicotine and nicotinic receptor involvement in neuropsychiatric disorders. Curr. Top. Med. Chem. 4: 267–282.
- 111 Novak, G., M. LeBlanc, C. Zai, et al . 2010. Association of polymorphisms in the BDNF, DRD1 and DRD3 genes with tobacco smoking in schizophrenia. Ann. Hum. Genet. 74: 291–298.
- 112
Novak, G.,
J. Boukhadra,
S.A. Shaikh,
et al
. 2009. Association of a polymorphism in the NRXN3 gene with the degree of smoking in schizophrenia: a preliminary study.
World J. Biol. Psychiatr.
10(Pt 3): 929–935.
10.1080/15622970903079499 Google Scholar
- 113 Novak, G., C.C. Zai, M. Mirkhani, et al . 2010. Replicated association of the NR4A3 gene with smoking behaviour in schizophrenia and in bipolar disorder. Genes Brain Behav. 9: 910–917.
- 114 Olincy, A., D.A. Young & R. Freedman. 1997. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol. Psychiatr. 42: 1–5.
- 115 Weinberger, A.H., K.A. Sacco, C.L. Creeden, et al . 2007. Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia. Schizophr. Res. 91: 217–225.
- 116 Williams, J.M., K.K. Gandhi, S.E. Lu, et al . 2010. Higher nicotine levels in schizophrenia compared with controls after smoking a single cigarette. Nicotine Tob. Res. 12: 855–859.
- 117 Williams, J.M., D.M. Ziedonis, F. Abanyie, et al . 2005. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophr. Res. 79: 323–335.
- 118 Tidey, J.W., D.J. Rohsenow, G.B. Kaplan & R.M. Swift. 2005. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. Drug Alcohol Depend. 80: 259–265.
- 119 Mackillop, J. & J.W. Tidey. 2011. Cigarette demand and delayed reward discounting in nicotine-dependent individuals with schizophrenia and controls: an initial study. Psychopharmacology 216: 91–99.
- 120 Lo, S., S.J. Heishamn, H. Raley, et al . 2011. Tobacco craving in smokers with and without schizophrenia. Schizophr. Res. 127: 241–245.
- 121 Tidey, J.W. & D.J. Rohsenow. 2009. Smoking expectancies and intention to quit in smokers with schizophrenia, schizoaffective disorder and non-psychiatric controls. Schizophr. Res. 115: 310–316.
- 122 Ahnallen, C.G. & J.W. Tidey. 2011. Personalized smoking environment cue reactivity in smokers with schizophrenia and controls: a pilot study. Psychiatr. Res. 188: 286–288.
- 123 Fonder, M.A., K.A. Sacco, A. Termine, et al . 2005. Smoking cue reactivity in schizophrenia: effects of a nicotinic receptor antagonist. Biol. Psychiatr. 57: 802–808.
- 124 Tidey, J.W., D.J. Rohsenow, G.B. Kaplan & R.M. Swift. 2005. Subjective and physiological responses to smoking cues in smokers with schizophrenia. Nicotine Tob. Res. 7: 421–429.
- 125 Strasser, A.A., W.B. Pickworth, F. Patterson & C. Lerman. 2004. Smoking topography predicts abstinence following treatment with nicotine replacement therapy. Cancer Epidemiol. Biomarkers Prev. 13(Pt 1): 1800–1804.
- 126 Killen, J.D. & S.P. Fortmann. 1997. Craving is associated with smoking relapse: findings from three prospective studies. Exp. Clin. Psychopharmacol. 5: 137–142.
- 127 Wing, V.C., T.G. Moss, R. Rabin & T.P. George. 2011. A comparison of delay discounting in smokers and non-smokers with schizophrenia and non-psychiatric controls. Addict. Behav. [Epub ahead of print]. doi: 10.1016/j.addbeh.2011.08.012.
- 128 Bickel, W.K., A.L. Odum & G.J. Madden. 1999. Impulsivity and cigarette smoking: delay discounting in current, never, and ex-smokers. Psychopharmacology 146: 447–454.
- 129 Addington, J., N. el-Guebaly, W. Campbell, et al . 1998. Smoking cessation treatment for patients with schizophrenia. Am. J. Psychiatr. 155: 974–976.
- 130 Ziedonis, D.M. & T.P. George. 1997. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr. Bull. 23: 247–254.
- 131 Tsoi, D.T., M. Porwal & A.C. Webster. 2010. Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis. Br. J. Psychiatr. 196: 346–353.
- 132 Cahill, K., L.F. Stead & T. Lancaster. 2011. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. CD006103.
- 133 Evins, A.E. & D.C. Goff. 2008. Varenicline treatment for smokers with schizophrenia: a case series. J. Clin. Psychiatr. 69: 1016.
- 134 Smith, R.C., J.P. Lindenmayer, J.M. Davis, et al . 2009. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr. Res. 110: 149–155.
- 135 Weiner, E., A. Buchholz, A. Coffay, et al . 2011. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr. Res. 129: 94–95.
- 136 Buchanan, R.W., R. Freedman, D.C. Javitt, et al . 2007. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr. Bull. 33: 1120–1130.
- 137 Olincy, A., J.G. Harris, L.L. Johnson, et al . 2006. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatr. 63: 630–638.
- 138 Freedman, R., A. Olincy, R.W. Buchanan, et al . 2008. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatr. 165: 1040–1047.
- 139 Koike, K., K. Hashimoto, N. Takai, et al . 2005. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr. Res. 76: 67–72.
- 140 Mihalak, K.B., F.I. Carroll & C.W. Luetje. 2006. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol. Pharmacol. 70: 801–805.
- 141 Patterson, F., C. Jepson, A.A. Strasser, et al . 2009. Varenicline improves mood and cognition during smoking abstinence. Biol. Psychiatr. 65: 144–149.
- 142 Loughead, J., R. Ray, E.P. Wileyto, et al . 2010. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol. Psychiatr. 67: 715–721.
- 143 Liu, M.E., S.J. Tsai, S.Y. Jeang, et al . 2011. Varenicline prevents affective and cognitive exacerbation during smoking abstinence in male patients with schizophrenia. Psychiatr. Res. [Epub ahead of print]. doi: 10.1016/jpsychres.2011.04.018.
- 144 Sacco, K.A., C. Creeden, E.L. Reutenauer, et al . 2009. Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia. Schizophr. Res. 107: 332–333.
- 145 Franklin, T.R., D. Harper, K. Kampman, et al . 2009. The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend. 103: 30–36.
- 146 Schmaal, L., L. Berk, K.P. Hulstijn, et al . Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. Eur. Addict. Res. 17: 211–216.
- 147 George, T.P., M.J. Sernyak, D.M. Ziedonis & S.W. Woods. 1995. Effects of clozapine on smoking in chronic schizophrenic outpatients. J. Clin. Psychiatr. 56: 344–346.
- 148 McEvoy, J., O. Freudenreich, M. McGee, et al . 1995. Clozapine decreases smoking in patients with chronic schizophrenia. Biol. Psychiatr. 37: 550–552.
- 149 Daskalakis, Z.J. & T.P. George. 2009. Clozapine, GABA(B), and the treatment of resistant schizophrenia. Clin. Pharmacol. Ther. 86: 442–446.
- 150 Wykes, T., V. Huddy, C. Cellard, et al . 2011. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am. J. Psychiatr. 168: 472–485.
- 151 Amiaz, R., D. Levy, D. Vainiger, et al . 2009. Repeated high-frequency transcranial magnetic stimulation over the dorsolateral prefrontal cortex reduces cigarette craving and consumption. Addiction 104: 653–660.
- 152 Eichhammer, P., M. Johann, A. Kharraz, et al . 2003. High-frequency repetitive transcranial magnetic stimulation decreases cigarette smoking. J. Clin. Psychiatr. 64: 951–953.
- 153 Frantseva, M.V., P.B. Fitzgerald, R. Chen, et al . 2008. Evidence for impaired long-term potentiation in schizophrenia and its relationship to motor skill learning. Cereb. Cortex. 18: 990–996.
- 154 Doran, N., B. Spring, D. McChargue, et al . 2004. Impulsivity and smoking relapse. Nicotine Tob. Res. 6: 641–647.
- 155 Krishnan-Sarin, S., B. Reynolds, A.M. Duhig, et al . 2007. Behavioral impulsivity predicts treatment outcome in a smoking cessation program for adolescent smokers. Drug Alcohol Depend. 88: 79–82.
- 156 Heerey, E.A., B.M. Robinson, R.P. McMahon & J.M. Gold. 2007. Delay discounting in schizophrenia. Cogn. Neuropsychiatr. 12: 213–221.
- 157 Ray, R., J. Loughead, Z. Wang, et al . 2008. Neuroimaging, genetics and the treatment of nicotine addiction. Behav. Brain Res. 193: 159–169.
- 158 Rose, J.E., F.M. Behm, T. Drgon, et al . 2010. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Mol. Med. 16: 247–253.
- 159 Lerman, C. 2006. Helping smokers quit through pharmacogenetics. LDI Issue Brief 11: 1–4.
